ArticleNephron2000
Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.
Article in Nephron, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01524705 (FLAT-SUGAR), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Who cites it
37 citing papers in PubMed, 121 citations in OpenAlex.
- Trial
- Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects.Diabetes care · 2013Trial
- Advances in the Identification of Novel Urinary Biomarkers for Diabetic Kidney Disease.Journal of diabetes research · 2026Review
- Article
- Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions.Biomedicines · 2024Review
- Therapeutic Potential of Curcumin, a Bioactive Compound of Turmeric, in Prevention of Streptozotocin-Induced Diabetes through the Modulation of Oxidative Stress and Inflammation.Molecules (Basel, Switzerland) · 2023Article
- Pathomechanisms of Diabetic Kidney Disease.Journal of clinical medicine · 2023Review
- Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis.Experimental and therapeutic medicine · 2023Article
- Fecal and Urinary Adipokines as Disease Biomarkers.Biomedicines · 2023Review
- Novel biomarkers for prognosticating diabetic kidney disease progression.International urology and nephrology · 2023Review
- Impact of exercise on renal function, oxidative stress, and systemic inflammation among patients with type 2 diabetic nephropathy.African health sciences · 2022Article
- Article
- Association Between High-Sensitivity C-Reactive Protein and Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus.Frontiers in endocrinology · 2022Observational
- The Correlation between Microalbuminuria and Thyroid Nodules in Type 2 Diabetic Mellitus.International journal of endocrinology · 2022Article
- The role of inflammation in diabetic kidney disease.The Korean journal of internal medicine · 2021Review
- Expression of Circulating MicroRNAs and Myokines and Interactions with Serum Osteopontin in Type 2 Diabetic Patients with Moderate and Poor Glycemic Control: A Biochemical and Molecular Study.BioMed research international · 2021Article
- Effects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease.Cell death & disease · 2020Article
- Transplantation of adipose-derived mesenchymal stem cell sheets directly into the kidney suppresses the progression of renal injury in a diabetic nephropathy rat model.Journal of diabetes investigation · 2020Article
- Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients.Experimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimInterleukin-6 (IL-6) promotes the growth of renal mesangial cells. IL-6 may play a major role in such mesangial proliferation, but there has been little research on IL-6 in relation to diabetic nephropathy because of the difficulty in measuring urinary and serum IL-6 levels. Using a newly developed, highly sensitive IL-6 assay, we studied the relationship between serum and urinary IL-6 and diabetic nephropathy.
methodsWe investigated 72 patients with type 2 diabetes. Urinary and serum IL-6 concentrations were measured using a chemiluminescent enzyme immunoassay with a detection limit of 0.11 pg/ml.
resultsThere was a significant increase of the serum IL-6 level as diabetic nephropathy progressed, with the level being 1.4 +/- 0.3 pg/ml in patients with normal albuminuria, rising to 2.4 +/- 0.6 pg/ml in patients with microalbuminuria and then to 4.4 +/- 0.8 pg/ml in those having proteinuria. The serum IL-6 level was also significantly correlated with fibrinogen and aortic pulse wave velocity. The urinary IL-6 level was also significantly increased in diabetic patients as nephropathy progressed. Both serum and urinary IL-6 levels were high in the group with nephropathy, but there was no correlation between the two.
conclusionThe urinary IL-6 level seems to be a good indicator of diabetic nephropathy, and atherosclerotic changes were related to the serum IL-6 level. The serum IL-6 may, therefore, be useful in the evaluation of atherosclerosis including nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.